Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities
They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body's reaction to then, affinity & avidity, CMC, and 'bead-on-a-string' approaches that some have used lately. Finally, a discussion of what the future holds.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Studio at Kendall Square
AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner
Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is just one of many ways larger companies help biotech entrepreneurs
Precision for Medicine CMO Harpreet Singh and Repertoire Immune Medicines CMO Robert Andtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs
Two leaders from the Harvard Biotech Club talk about their experience in the club, its new podcast, The Pulse, and an upcoming career fair on September 19th
Get summaries like this every morning.
Free AI-powered recaps of The Studio at Kendall Square and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.